Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.30 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1269
Sealed predictions
- REEP5 in dopamine neurons, braak-0.09 (p 0.815) → -0.07 (p 0.856)receipt 1276
Swarm cases
receipt 1276: REEP5 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.867, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.10, sign flips 4; without severely affected donors -0.04 (p 0.867, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.61 (p 0.0067, n 18) vs -0.04 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for REEP5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up REEP5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.00 p 1.000 (needs p < 0.0010)
Receipts
loading the receipts